Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.68 +0.82 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >
'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi
First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop... 
Via Benzinga
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony. 
Via InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Could This Medicine Be the Next Winner for Novartis?
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
Exposures Product Safety
2 Top Biotech Stocks to Buy Right Now
These drugmakers are among the most dominant in the world. 
Via The Motley Fool
Why Shares of MacroGenics Are Jumping Thursday
The company announced second-quarter earnings. 
Via The Motley Fool
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Neither is performing particularly well this year compared to the broader market, but don't let that chase you away. 
Via The Motley Fool
Amazon's Boon for Diabetes Patients - Streamlining Pharmacy Discounts
Amazon.Com Inc's (NASDAQ: AMZN) online pharmacy launched a new initiativ 
Via Benzinga
Looking Into Sanofi's Recent Short Interest
Via Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tiziana Life Sciences, Inc. 
Via Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary... 
Via Benzinga
The Top Healthcare Stocks to Buy With $100
There's no need to have a fortune to invest in stocks. 
Via The Motley Fool
Sanofi (SNY) Q2 2023 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories
Bloomberg 
Via Benzinga
Sanofi Reports Lower Q2 Earnings, But Lifts 2023 Outlook On New Drug Launches
Sanofi SA (NASDAQ: SNY) reported a 1% decline in Q2 business operating in 
Via Benzinga
Sanofi's Earnings Outlook
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon
Stocks appear to have shaken off Thursday's negativity and are positioned for a rebound on upbeat earnings. 
Via Benzinga
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss... 
Via Benzinga
Earnings Scheduled For July 28, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion. 
Via Benzinga
7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023
Even some of the top players of the market don’t get the attention they deserve, making these blue-chip stocks compelling. 
Via InvestorPlace
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
From Recludix Pharma, Inc.
Via GlobeNewswire
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
Wall Street Journal 
Via Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
The FDA approved AstraZeneca Plc (NASDAQ: 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.